摘要
前列腺癌(prostate cancer,PCa)是发生于前列腺组织的上皮性恶性肿瘤,它是仅次于肺癌的男性第二大常见癌症,影响着全球数百万男性。microRNA(miRNA)是一种长度为20~22nt的非编码小RNA,在转录后调控基因表达,miRNA参与了细胞周期进展、细胞增殖、细胞凋亡、细胞迁移等几乎所有重要的生物生命过程的调控。最近越来越多的研究表明,miRNA参与了包括PCa在内的各种人类肿瘤的发生,本综述总结了现阶段与PCa相关的miRNA的研究进展,分析了PCa患者体内表达失调的miRNA在PCa发病机制、诊断和治疗中的作用,并且重点阐述了miRNA在去势抵抗性前列腺癌(castration-resistant prostate cancer,CRPC)诊断和治疗中的作用。
Prostate cancer(PCa)is an epithelial malignancy that occurs in the prostate tissue and is the second most common cancer in men after lung cancer,affecting millions of men worldwide.MicroRNA(miRNA)is a non-coding small RNA of length 20-22 nt that regulates gene expression post-transcriptionally.miRNAs are involved in the regulation of almost all important biological life processes such as cell cycle progression,cell proliferation,cell apoptosis,and cell migration.Recently,more and more studies have shown that miRNAs are involved in the occurrence of various human tumors including PCa.This review summarizes the current research progress of PCA-related miRNAs,and analyzes the role of malregulated miRNAs in the pathogenesis,diagnosis and treatment of PCa.In addition,the role of miRNA in the diagnosis and treatment of castration-resistant prostate cancer(CRPC)is emphasized.
作者
丁昊
高振华
郑云
DING Hao;GAO Zhenhua;ZHENG Yun(Faculty of Information Engineering and Automation,Kunming University of Science and Technology,Kunming 650500,Yunnan,China;Department of Urology,The First Affiliated Hospital of Kunming Medical University,Kunming 650032,Yunnan,China;Institute of Primate Translational Medicine,Kunming University of Science and Technology,Kunming 650500,Yunnan,China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2022年第6期696-708,共13页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
科技部国家重点研发计划课题(2018YFA0108502)
国家自然科学基金地区基金(31760314)
国家地区科学基金项目(81960133)
云南省高层次人才培养计划“青年拔尖人才”专项培养经费(RLQB20200005)。
